ArticleDiscover oncology2025
Combination of cellular retinoic acid-binding protein 2 overexpression and all-trans retinoic acid synergistically inhibits oesophageal squamous cell carcinoma progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveAll-trans retinoic acid (ATRA) has demonstrated great potential in cancer treatment; however, the molecular mechanism for the anti-tumour effects of Cellular retinoic acid-binding protein 2 (CRABP2) and ATRA in oesophageal squamous cell carcinoma (ESCC) remains unclear.
methodsA strategy of transfecting KYSE-150 cells with vectors or CRABP2 overexpression was applied in this study. Changes in cell proliferation, migration, invasion and apoptosis in OE-NC, OE-CRABP2, OE-NC + ATRA and OE-CRABP2 + ATRA groups were observed. The location of CRABP2 with ATRA and the expression of key proteins that may be involved were detected. The volume and weight of subcutaneous grafted tumours in nude mice were compared in vivo, cell morphology was observed through haematoxylin and eosin (HE) staining, and cell apoptosis was detected using TUNEL staining.
resultsWe determined that, in vitro, CRABP2 combined with ATRA best inhibited the proliferation, migration, invasion and cell cycle of ESCC and promoted its apoptosis. Oxidative stress, the mitochondrial pathway, p53 and the NF-κB pathway may be involved in the synergistic inhibitory effect of CRABP2 and ATRA. In vivo, tumour volume in the OE-CRABP2 + ATRA group was the smallest and tumour growth was the slowest. The HE results demonstrated improved cell differentiation in the OE-CRAB2 + ATRA group, and TUNEL staining revealed that CRABP2 and ATRA had the strongest promoting effect on cell apoptosis, with the degree of cell apoptosis the greatest with the participation of ATRA.
conclusionThe combination of CRABP2 overexpression and ATRA synergistically inhibits ESCC progression. All-trans retinoic acid may be a candidate therapy for ESCC, and CRABP2 overexpression could enhance the efficacy of ATRA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.